Best Genomics Companies in New York City, United States
The 95 best Genomics companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kallyope.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in New York City
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Kallyope Discovering novel therapeutics for neurological and metabolic diseases | $479M | 37 mo ago | Series D | 84 84 → 64 (-24%) | Charles Zuker Co-Founder | 134 patents NK3 receptor modulators for treating neurological and metabolic disorders | — |
| 2 | Neurogene Developer of therapeutics for the treatment of rare neurological disorders | $184M | 66 mo ago | Public | 83 | — | 7 patents Engineered protein therapeutics for T‑reg activation and optimized GALC enzyme replacement. | — |
| 3 | MeiraGTx Developer of gene therapies for ocular and neurodegenerative diseases | $130M | 31 mo ago | Public | 358 358 → 419 (+17%) | — | 14 patents Therapeutic modulation of the retromer complex for neurodegenerative disease treatment | — |
| 4 | Prevail Therapeutics Developer of gene therapies for treating neurodegenerative and rare diseases | $125M | 86 mo ago | Acquired | 70 | Asa Abeliovich Founder & CEO | 227 patents Developing gene therapy vectors targeting lysosomal storage disease treatments. | — |
| 5 | C2i Genomics Provider of liquid biopsy for post cancer surgery monitoring | $112M | 62 mo ago | Acquired | 64 | Ezra Sofer Co-Founder | — | — |
| 6 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | Series B | 21 21 → 41 (+95%) | Samuel Bakhoum Co-Founder | — | 1 job opening |
| 7 | Rocket Pharma Developer of gene-modified cell therapies for the treatment of rare diseases 60Funding top 24%Tech top 32%Market top 42%News top 46% All 7 signals ▾Fundingtop 24% Techtop 32% Markettop 42% Newstop 46% Moattop 48% Growthtop 50% Globalbottom 32% Funding: Raised $83.2M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Tech: 54 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 60/100 | $83M | 18 mo ago | Public | 268 268 → 222 (-17%) | — | — | 1 internship |
| 8 | BioArray Solutions Beadchip for biomolecular analysis | $57M | 228 mo ago | Acquired | 28 | Jeffrey Binder CEO | 288 patents Multiplexed nucleic‑acid detection and typing using micro‑particle array platforms | — |
| 9 | Gotham Therapeutics Developer of therapeutics for cancer | $54M | 92 mo ago | Series A | 4 | — | — | — |
| 10 | Provista Diagnostics Molecular oncology diagnostics company | $42M | 97 mo ago | Acquired | 2 | — | 22 patents Cancer biomarker diagnostics for early detection of breast and ovarian cancers | — |
| 11 | IVERIC bio Developer of gene therapy solutions to treat retinal diseases | $35M | 91 mo ago | Acquired | 94 | — | — | — |
| 12 | Phosphorus Provider of next-generation diagnostics and tools for clinicians and researchers | $31M | 70 mo ago | Deadpooled | 28 | — | — | — |
| 13 | Celmatix Pioneering ovarian health therapeutics for women's unique biological needs | $25M | 102 mo ago | Series C | 27 27 → 15 (-44%) | Piraye Beim Founder and CEO | 136 patents FSH receptor modulators for fertility and peripheral melatonin receptor agonist delivery | — |
| 14 | AcuamarkDx Provider of non-invasive screening test for early detection of cancer | $20M | 25 mo ago | Series A | 6 | Bernard Peperstraete Cofounder & CEO | — | — |
| 15 | Genoplan Developer of genetic test kits for health analysis | $20M | 93 mo ago | Series B | 16 | — | 11 patents AI-based polygenic risk scoring and disease risk prediction using deep learning models | — |
| 16 | Redpin Therapeutics Developer of cell therapies for Neurological and Psychiatric disorders | $17M | 75 mo ago | Acqui-Hired | 10 | — | — | — |
| 17 | Gencove Cloud platform for personal genomics | $16M | 55 mo ago | Series A | 31 | — | 2 patents Integrated low‑pass whole‑genome and targeted DNA sequencing for comprehensive genomic analysis | — |
| 18 | Recombine Genetic testing services | $12M | 119 mo ago | Acquired | 79 | — | — | — |
| 19 | Meves Pharmaceuticals Provider of nucleoside based therapies for treating mitochondrial depletion disorders | $11M | 99 mo ago | Deadpooled | — | Joshua Grass CEO | — | — |
| 20 | Newtopia Provider of health management platform for employers and insurers | $11M | 27 mo ago | Public | 121 | — | — | — |
| 21 | Cyprium Developer of therapeutics for rare pediatric diseases | $7M | 56 mo ago | Series A | — | Lung S Yam Co-Founder & CEO | — | — |
| 22 | Morgan and Mendel Genomics Provider of technology platform based on a combination of flow cytometry and Western blot | $4M | 93 mo ago | Funding Raised | 7 | — | — | — |
| 23 | Summit Biomedical Imaging Developer of diagnostic solutions for the early detection of cancer diseases | $4M | 15 mo ago | Funding Raised | 3 | Thomas Reiner Co-Founder & Scientific Advisor | — | — |
| 24 | Episteme Prognostics Developer of precision therapeutics for pancreatic cancer | $4M | 37 mo ago | Series A | 2 | Surajit Dhara Founder & CEO | 6 patents Epigenomic profiling of chromatin accessibility using qPCR‑based array assays | — |
| 25 | Exavir Developer of therapeutics for the treatment of viral diseases | $4M | 34 mo ago | Seed | 3 | Howard Gendelman Co-Founder | — | — |
| 26 | Gene Link Supplier of custom oligonucleotides, siRNA, fluorescent probes, genetic tools, and reagents | $3M | 158 mo ago | Public | — | Ali Javed Founder & Director | — | — |
| 27 | Chimerna Developer of RNA therapeutics | $3M | 16 mo ago | Funding Raised | — | Brian Pickering CEO | — | — |
| 28 | Isabl Developer of a medical diagnosis platform to analyze genome of cancer patients | $3M | 38 mo ago | Seed | 5 | Juan Medina Co-Founder and CTO | — | — |
| 29 | GTN Provider of quantum computing-based software for drug discovery | $3M | 97 mo ago | Deadpooled | 3 | — | — | — |
| 30 | OneThree Biotech Developer of AI-based drug discovery and development platform | $3M | 77 mo ago | Seed | 9 | — | — | — |
| 31 | RUMI Scientific Provider of proprietary human stem cell platform for screening genetic diseases | $2M | 25 mo ago | Funding Raised | 6 | Ali Brivanlou Co-Founder | — | — |
| 32 | SolveBio Provider of genomic data analytics platform | $2M | 101 mo ago | Acquired | 11 | David Gross Co-Founder | — | — |
| 33 | Reme-D.Inc Developer of diagnostic kits for both human and animal diseases 27Patents top 30%Global top 38%Innovation top 41%Funding top 44% All 7 signals ▾Patentstop 30% Globaltop 38% Innovationtop 41% Fundingtop 44% Talentbottom 49% Techbottom 30% Marketbottom 25% Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | Seed | — | Salma Tammam Founder & CEO | 42 patents Hydraulic control valves and pistons for rotary steerable drilling tools | — |
| 34 | AzurRx BioPharma Provider of recombinant proteins for the treatment of gastrointestinal diseases | $1M | 65 mo ago | Public | 10 | — | — | — |
| 35 | CyteQuest Provider of in vitro electroporation based assay for single-cell analysis | $1M | 47 mo ago | Seed | 3 | Tom Corso Co-Founder | 19 patents High-throughput microfluidic electroporation devices for cellular gene delivery | — |
| 36 | Symbiotic Health Develops microbiome-based therapeutics for gastrointestinal infection | $1M | 116 mo ago | Deadpooled | 7 | Gerard Honig CEO and Founder | — | — |
| 37 | VentriNova Developer of viral vector-based gene therapy for regenerating heart muscle cells | $1M | 201 mo ago | Deadpooled | — | Hina Chaudhry Founder | — | — |
| 38 | Tavec Pharmaceuticals Developer of miRNA-loaded exosome-based therapies for cancer | $850K | 132 mo ago | Acquired | — | Robert McNeil CEO | — | — |
| 39 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | Public | 107 | — | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
| 40 | FitBiomics Provider of next-generation sequencing of microbiome of elite athletes | $816K | 147 mo ago | Funding Raised | 15 | Aleksandar Kostic Co-Founder | 12 patents Probiotic nutritional supplements enhancing human health and athletic performance | — |
| 41 | GeneCentrix GeneCentrixGeneCentrix is a big-data bioinformatics company that builds tools for early-stage drug discovery. | $768K | 132 mo ago | Deadpooled | — | Doreen Tivon Co-Founder & CEO | — | — |
| 42 | Epitor Therapeutics Developer of therapeutics based on gene editing technologies | $698K | 21 mo ago | Funding Raised | — | Megan McGill CEO | — | — |
| 43 | FIND Genomics Provider of cloud-based bioinformatics software for genomic sequencing and tracking of cell line | $259K | 50 mo ago | Funding Raised | 3 | Sophie Zaaijer Founder & CEO | — | — |
| 44 | Helex Provider of next-generation gene-editing therapies | $250K | 7 mo ago | Seed | 22 | Anirudh Nishtala Co-Founder & COO | 8 patents Lipid nanoparticle delivery systems for tissue-specific CRISPR gene editing therapies. | — |
| 45 | Girihlet Developer of a platform targeting the immune system and mitochondria to understand and fight disease | $250K | 113 mo ago | Seed | 2 | — | 4 patents TCR/BCR chain pairing analysis and pure mitochondrial DNA isolation technologies. | — |
| 46 | Genetic Intelligence AI based online platform for genome-based precision medicine solution | $225K | 95 mo ago | Funding Raised | — | Bertrand Adanve Founder & CEO | 17 patents Therapeutic small‑molecule modulators of MYC, IL‑2 signaling, and FNIP1/2 gene expression | — |
| 47 | Genomic Expression Provider of pharmacogenomic solutions for cancer | $200K | 66 mo ago | Seed | 12 | — | — | — |
| 48 | Signatur Biosciences Developer of molecular diagnostic kits compatible with standard PCR equipment | $125K | 12 mo ago | Seed | 6 | Dame Stevens Co-Founder | — | — |
| 49 | Humane Genomics Developer of cancer therapeutics using the oncolytic virus | $125K | 16 mo ago | Seed | 8 | Chad Moles Co-Founder & CSO | 10 patents Engineered oncolytic viruses and modular viral genome platforms for targeted cancer therapy | — |
| 50 | Arctic Capture Provider of carbon capture solution | $125K | 24 mo ago | Seed | — | Ankit Singhal Co-Founder & CEO | — | — |
Top 12 Genomics companies in New York City
#1
Series B · New York City, New York · founded 2019 · 21 employees$87.2Mraised▾
Developer of therapeutics for cancer treatment. The company is developing compounds to target chromosomal instability and related pathways to inhibit genomic instability and disease progression. It also developing proprietary imaging technologies to identify chromosomal instability cancers.
- Sep 2025Series B$30.1M
- May 2024Series A$15M
- Mar 2023Series A$60.2M
- Apr 2021Seed—
#2
Public · New York City, New York · founded 2015 · 268 employees$83.2Mraised▾
Developer of gene-modified cell therapies for the treatment of rare diseases. It offers adeno-associated viral and lentil virus gene therapies which include RP-L02 for Fanconi anemia, RP-L201 for leukocyte adhesion deficiency, RP-L301 for pyruvate kinase deficiency, RV-l501 for Danon disease, RP-A601 for PKP2-ACM, and others.
- Dec 2024Post IPO$5M
- Aug 2021Post IPO$26.4M
- Nov 2020Grant (prize money)$3.7M
- Apr 2019Grant (prize money)$6.5M
#3
Seed · New York City, New York · founded 2022$1.5Mraised▾
Developer of diagnostic kits for both human and animal diseases. It offers kits for nucleic acid extraction, amplification, sequencing, and detection to diagnose both infectious and non-infectious diseases.
- Apr 2026Seed$500K
- Nov 2023Grant (prize money)$10K
- Seed$1M
#4
Public · New York City, New York · founded 2014 · 107 employees$845Kraised▾
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include "CarpX" a minimally invasive device to treat carpal tunnel syndrome, "PortIO" a novel, implantable, intraosseous vascular access device, and "DisappEAR" antimicrobial resorbable ear tubes, and many more.
- Feb 2026Post IPO$30M
- Feb 2025Post IPO$2.4M
- Jan 2025Post IPO$2.7M
- Sep 2024Grant (prize money)$892.1K
#5
Series D · New York City, New York · founded 2014 · 84 employees$479Mraised▾
Discovering novel therapeutics for neurological and metabolic diseases. The company focuses on addressing significant health challenges by developing effective and well-tolerated agents. Utilizing the Klarity Platform, scientists investigate medicines targeting metabolism, including type 2 diabetes and obesity, and neurological disorders like migraine and pain. The company pursues innovative approaches to medicine discovery, integrating technologies for differentiated therapeutic development. With a team of scientists and drug developers, the company fosters a culture of innovation and collaboration to advance human health. The company operates in the pharmaceutical and biotechnology sectors, focusing on research and development to create solutions for unmet medical needs. The company's work has a direct social impact by aiming to improve the lives of patients and families affected by these diseases.
- May 2023Grant (prize money)$8.2M
- Feb 2022Series D$236M
- Mar 2020Series C$112M
- Dec 2018Series B$21M
#6
Funding Raised · New York City, New York · founded 2016 · 3 employees$4.1Mraised▾
Developer of diagnostic solutions for the early detection of cancer diseases. The company has developed a fluorescent small molecule, PARPi-FL by using propitiatory technology that helps to detect early stage of PARP1, which is common in certain cancers. It also helps in diagnosing In vivo oral cancer, Ex vivo cervical cancer, Ex vivo esophageal cancer, Ex vivo breast cancer, and more.
- Mar 2025Grant (prize money)$1.8M
- Sep 2020Grant (prize money)$1.8M
- Mar 2019Grant (prize money)$300K
- Sep 2018Grant (prize money)$299.9K
#7
Funding Raised · New York City, New York · founded 2019$3.4Mraised▾
Chimerna is a developer of RNA therapeutics using its proprietary platform. The Tornadu platform is used to stimulate the cells to produce circular RNA and aptamers that are required to treat the disease. The platform is being used to develop RNA therapeutics to treat autosomal-dominant polycystic kidney disease, Alzheimer's disease, and Parkinson's disease.
- Feb 2025Grant (prize money)$256.2K
- Feb 2025Grant (prize money)$302.6K
- Jan 2025Grant (prize money)$302.6K
- Jan 2024Grant (prize money)$297.6K
#8
Public · New York City, New York · founded 2015 · 358 employees$130Mraised▾
Developer of gene therapies for ocular and neurodegenerative diseases. Its drug pipeline includes AAV-RPGR to treat the most common form of X-linked retinitis pigmentosa, AAV-RPE65 to treat rare pediatric disease, and AAV-GAD is an investigational gene therapy to treat Parkinson's disease.
- Oct 2023Post IPO$30M
- Feb 2019Post IPO$100M
- Seed—
#9
Seed · New York City, New York · founded 2021 · 22 employees$250Kraised▾
Provider of next-generation gene-editing therapies. By using proprietary genomics data, bioinformatics, and intelligent data-driven platform the company has developed CRISPR-based genome editing therapeutics.
- Oct 2025Seed$3.5M
- Oct 2021Seed$250K
#10
Series A · New York City, New York · founded 2013 · 6 employees$20Mraised▾
Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.
- May 2024Series A$4.9M
- Jul 2022Series A$11.3M
- Sep 2019Seed$2.3M
- Nov 2016Seed$1.5M
#11
Public · New York City, New York · founded 2008 · 121 employees$10.7Mraised▾
Provider of health management platform for employers and insurers. It offers weight related genes recommends the exercise program and gets personalized coaching from the care team. It has API with wearables to track nutrition and daily activity for employees and individuals. The platform provides online information and programs for different health problems such as Type 2 Diabetes, Hypertension, Heart Disease, and Obesity, disease prevention programs, weight management programs, and more.
- Feb 2024Post IPO$550.3K
- Mar 2023Post IPO—
- Apr 2022Post IPO$3.4M
- Nov 2020Post IPO$711.6K
#12
Public · New York City, New York · founded 2001 · 83 employees$183.5Mraised▾
Neurogene is developing therapeutics for the treatment of rare neurological disorders. The company's lead product candidate utilizes an adeno-associated virus (AAV) to deliver a healthy copy of a gene to people with a defect in the disease-causing gene. It is developing therapeutics for different diseases like aspartylglucosaminuria, Charcot-Marie Tooth disease, and more.
- Dec 2020Series B$115M
- Feb 2019Series A$68.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Baluch Mohamed Khoso7
- Genomsys7
- Microsoft6
- Contamination Source Identificat6
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.